Economic evaluation of the use of non-vitamin K oral anticoagulants in patients with atrial fibrillation on antiplatelet therapy: a modelling analysis using the healthcare system in the Netherlands

European Heart Journal. Quality of Care & Clinical Outcomes
Naoual BennaghmouchJ M Ten Berg

Abstract

Non-vitamin K oral anticoagulants (NOACs) have consistently demonstrated superior efficacy in terms of stroke prevention and safety in terms of bleeding over vitamin K antagonist (VKA) in patients with non-valvular atrial fibrillation (AF). The potential use of NOACs in AF patients requiring antiplatelet therapy (APT) has only been assessed in small meta-analyses reporting consistent benefits of NOACs over VKAs. However, the prescription costs of NOACs are higher than those of VKAs. The aim of his study was to estimate the cost-effectiveness (CE) of NOACs compared to VKAs in patients with non-valvular AF also requiring APT with the Dutch healthcare system used as a surrogate of many European healthcare systems. A decision tree was constructed to analyse the CE of NOACs compared to VKAs in patients with non-valvular AF with an indication for APT over a horizon of 1 year. Beside the base-case analysis, univariate probabilistic sensitivity and two sensitivity analyses were performed: first, we assessed the impact of VKA home monitoring; second, we varied the NOACs price assuming patent expiration. Use of NOACs instead of VKA is associated with a health gain of 0.0171 quality-adjusted life years (QALYs) and with an incremental cost...Continue Reading

References

May 15, 2001·European Heart Journal·B A van Hout, M L Simoons
Jun 8, 2002·Stroke; a Journal of Cerebral Circulation·Y B W E M RoosM Vermeulen
Oct 5, 2002·BMJ : British Medical Journal·Andrew D BlannGregory Y H Lip
May 30, 2003·Cost Effectiveness and Resource Allocation : C/E·Job Van ExelWilma JM Scholte Op Reimer
May 30, 2003·Cost Effectiveness and Resource Allocation : C/E·Benjamin JohnsRaymond Hutubessy
Nov 6, 2007·The New England Journal of Medicine·Deepak L Bhatt
Sep 5, 2008·PharmacoEconomics·Julia Earnshaw, Gavin Lewis
Sep 1, 2009·The New England Journal of Medicine·Stuart J ConnollyUNKNOWN RE-LY Steering Committee and Investigators
Jan 1, 2010·The New England Journal of Medicine·Donald Stuart Houston, Ryan Zarychanski
Nov 19, 2010·Cost Effectiveness and Resource Allocation : C/E·Stefan A BaetenLouis W Niessen
Aug 13, 2011·The New England Journal of Medicine·Manesh R PatelUNKNOWN ROCKET AF Investigators
Aug 30, 2011·The New England Journal of Medicine·Christopher B GrangerUNKNOWN ARISTOTLE Committees and Investigators
Aug 25, 2012·Thrombosis and Haemostasis·Pablo Alonso-CoelloGordon Guyatt
Oct 23, 2012·EuroIntervention : Journal of EuroPCR in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology·J Gustav SmithJesper van der Pals
Mar 5, 2013·Netherlands Heart Journal : Monthly Journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation·R R SoekhlalS S Tan
Mar 14, 2013·JAMA : the Journal of the American Medical Association·Adnan K ChhatriwallaUNKNOWN National Cardiovascular Data Registry
Mar 30, 2013·Stroke; a Journal of Cerebral Circulation·Tai Hwan ParkByung-Woo Yoon
Nov 21, 2013·The New England Journal of Medicine·Robert P GiuglianoUNKNOWN ENGAGE AF-TIMI 48 Investigators
May 20, 2014·Journal of Oncology Practice·Paul Goldberg, Rena M Conti
Jul 6, 2014·Stroke; a Journal of Cerebral Circulation·Alvaro AlonsoKamakshi Lakshminarayan
Oct 19, 2014·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Talitha I VerhoefAnke Hilse Maitland-van der Zee
Jan 4, 2015·BMJ : British Medical Journal·Larissa ShamseerUNKNOWN PRISMA-P Group
Apr 25, 2015·Journal of the American College of Cardiology·Deepak L Bhatt
Jul 29, 2015·BMC Health Services Research·Misericòrdia CarlesPablo Alonso-Coello
Jan 23, 2016·Heart·Muhammad Jawad-Ul-Qamar, Paulus Kirchhof
Mar 17, 2016·Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz·Paulus KirchhofUlrich Schotten
Sep 7, 2016·American Heart Journal·Rohan ShahUNKNOWN ROCKET AF Steering Committee Investigators

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atrial Filbrillation

Atrial fibrillation refers to the abnormal heart rhythm characterized by rapid and irregular beating of the atria. Here is the latest research.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.